Table 1.
Baseline characteristics of control and GD groups
| Con group (n = 33) | GD group (n = 65) | p value | |
|---|---|---|---|
| Age (years) | 27.00 (26.00–29.00) | 30.00 (25.00–40.50) | 0.0547 |
| Sex(male/female) | 10/23 | 18/47 | 0.8159 |
| BMI (kg/m2) | 20.03 (19.29–21.96) | 20.81 (18.93–22.76) | 0.4177 |
| FT3 (pg/mL) | 3.04 (2.77–3.34) | 18.85(12.60–28.88) | <0.0001∗∗∗∗ |
| FT4 (ng/dL) | 1.14 (1.01–1.28) | 6.53 (4.19–11.66) | <0.0001∗∗∗∗ |
| TSH (μIU/mL) | 2.43 (1.80–3.29) | 0.0025 (0.0025–0.005) | <0.0001∗∗∗∗ |
| TRAb (U/L) | 1.37 (0.35–1.76) | 5.10 (3.10–19.00) | <0.0001∗∗∗∗ |
| TPO-Ab (IU/mL) | 23.62 (20.13–26.90) | 133.70 (24.25–320.90) | <0.0001∗∗∗∗ |
| TG-Ab (IU/mL) | 5.00 (5.00–7.82) | 371.2 (56.72–791.00) | <0.0001∗∗∗∗ |
GD, Graves' disease; BMI, body mass index; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone; TPO-Ab, thyroperoxidase antibody; TG-Ab, thyroglobulin antibody; TRAb, thyrotrophin receptor antibody. Data are median (25th–75th percentile) unless otherwise indicated. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.